Emergent Biosolutions Inc (EBS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 3 - Initial statement of beneficial ownership of securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 144 - Report of proposed sale of securities

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention...

Form 8-K - Current report

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net...

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion...

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a...

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety...

Form 8-K - Current report

Form 8-K - Current report